EpiVax. has been granted a patent for T cell epitopes that include peptide chains from immunoglobulin regions. The patent covers methods for their use and production, specifically detailing a chimeric polypeptide combining an immunoglobulin fragment with a non-immunoglobulin biologically active molecule. GlobalData’s report on EpiVax gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on EpiVax, Peptide pharmacophores was a key innovation area identified from patents. EpiVax's grant share as of July 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Chimeric polypeptides with immunoglobulin fragments and active molecules
The granted patent US12016909B2 describes a chimeric polypeptide that consists of two linked polypeptide chains. The first chain is a fragment of an immunoglobulin with a specific amino acid sequence (SEQ ID NO: 12), while the second chain comprises a biologically active molecule that is not an immunoglobulin. The claims detail various configurations of the chimeric polypeptide, including the positioning of the second polypeptide chain at either the N-terminus or C-terminus of the first chain. Additionally, the chimeric polypeptide may include isolated T-cell epitope polypeptides and can be composed of biologically active molecules such as viral proteins, bacterial proteins, FVIII molecules, autoimmune antigens, and allergens.
Furthermore, the patent outlines a method for inducing regulatory T-cells to suppress immune responses in a subject by administering a therapeutically effective amount of the described chimeric polypeptide. The claims specify that the second polypeptide chain can be fused to either terminus of the first chain and may also include T-cell epitopes. The biologically active molecules involved in this method are similarly categorized as non-immunoglobulin polypeptides, including the aforementioned types. The patent emphasizes the potential therapeutic applications of the chimeric polypeptide in modulating immune responses, highlighting its relevance in immunology and therapeutic development.
To know more about GlobalData’s detailed insights on EpiVax, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
